United StatesÚltimas notícias

SmartFinancial (NYSE:SMBK), the parent company of SmartBank, today reported net income of $13.7 million, or $0.81 per diluted common share, for the first quarter ended March 31, 2026.

Bank of Hawai‘i (NYSE:BOH) reported a sequential increase in net interest income for the first quarter ended March 31, 2026, as the institution began to realize the benefits of a shifting interest rate environment.

Solidion Technology (NASDAQ:STI), an advanced battery materials provider, has finalized a binding strategic patent monetization agreement with Hilco Global’s IP Services Practice.

Agnico Eagle Mines (NYSE:AEM) and Rupert Resources announced today that they have entered into a definitive arrangement agreement for Agnico Eagle to acquire all remaining outstanding common shares of Rupert.

USA Rare Earth (NASDAQ:USAR) has announced a definitive agreement to acquire Serra Verde Group for a total consideration of approximately $2.8 billion.

Greenwich LifeSciences (NASDAQ:GLSI) today presented a significant update on its clinical progress at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

Ennis (NYSE:EBF), a manufacturer of printed business products and apparel, today announced financial results for the fourth quarter and the full fiscal year ended February 28, 2026.

Cleveland-Cliffs (NYSE:CLF), the largest flat-rolled steel producer in North America, reported a significant sequential increase in operational volume and revenue for the first quarter ended March 31, 2026.

Apple (NASDAQ:AAPL) is facing an accelerated timeline for potential antitrust penalties in India after the nation’s competition watchdog fast-tracked a decision to a final hearing next month.

Oculis Holding (NASDAQ:OCS), a global biopharmaceutical company focused on ophthalmic breakthroughs, announced today the completion of the final patient visits in its DIAMOND Phase 3 clinical program.

Monopar Therapeutics (NASDAQ:MNPR) reported positive topline results from its Phase 3 FoCus study, marking a significant milestone in the development of ALXN1840 for patients with Wilson disease.

Sutro Biopharma (NASDAQ:STRO) unveiled a series of preclinical successes at the 2026 American Association for Cancer Research (AACR) Annual Meeting, reinforcing its leadership in the design of next-generation antibody-drug conjugates (ADCs).